Defining Biological Subsets in Systemic Lupus Erythematosus: Progress Toward Personalized Therapy

Nailú Angélica Sinicato, Mariana Postal, Simone Appenzeller, Timothy B. Niewold

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is a heterogeneous disease with respect to disease severity, response to treatment, and organ damage, the pathogenesis of which includes immunological mechanisms that are driven by both genetic and environmental factors. There are clear differences in the pathogenesis of SLE between patients of different ancestral backgrounds, including differences in genetic risk factors, immunological parameters, and clinical manifestations. Patients with high and low levels of type I interferon (IFN) in circulation represent one major biological subset within SLE, and these two groups of patients are present in all ancestral backgrounds. Genetic factors, autoantibodies, and levels of other cytokines all differ between high and low IFN patients. This distinction has also been important in predicting response to treatment with anti-type I IFN therapies, providing a precedent in SLE for biological subsets predicting treatment response. This review highlights some recent developments in defining biological subsets of SLE based on disease pathophysiology, and we speculate how this improved knowledge of disease heterogeneity will inform our efforts to personalize therapy in this disease.

Original languageEnglish (US)
Pages (from-to)81-88
Number of pages8
JournalPharmaceutical Medicine
Volume31
Issue number2
DOIs
StatePublished - Apr 1 2017

Fingerprint

Systemic Lupus Erythematosus
Interferons
Therapeutics
Interferon Type I
Autoantibodies
Cytokines

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Defining Biological Subsets in Systemic Lupus Erythematosus : Progress Toward Personalized Therapy. / Sinicato, Nailú Angélica; Postal, Mariana; Appenzeller, Simone; Niewold, Timothy B.

In: Pharmaceutical Medicine, Vol. 31, No. 2, 01.04.2017, p. 81-88.

Research output: Contribution to journalArticle

Sinicato, Nailú Angélica ; Postal, Mariana ; Appenzeller, Simone ; Niewold, Timothy B. / Defining Biological Subsets in Systemic Lupus Erythematosus : Progress Toward Personalized Therapy. In: Pharmaceutical Medicine. 2017 ; Vol. 31, No. 2. pp. 81-88.
@article{77258ed8b7e2418b8c6aecd697576716,
title = "Defining Biological Subsets in Systemic Lupus Erythematosus: Progress Toward Personalized Therapy",
abstract = "Systemic lupus erythematosus (SLE) is a heterogeneous disease with respect to disease severity, response to treatment, and organ damage, the pathogenesis of which includes immunological mechanisms that are driven by both genetic and environmental factors. There are clear differences in the pathogenesis of SLE between patients of different ancestral backgrounds, including differences in genetic risk factors, immunological parameters, and clinical manifestations. Patients with high and low levels of type I interferon (IFN) in circulation represent one major biological subset within SLE, and these two groups of patients are present in all ancestral backgrounds. Genetic factors, autoantibodies, and levels of other cytokines all differ between high and low IFN patients. This distinction has also been important in predicting response to treatment with anti-type I IFN therapies, providing a precedent in SLE for biological subsets predicting treatment response. This review highlights some recent developments in defining biological subsets of SLE based on disease pathophysiology, and we speculate how this improved knowledge of disease heterogeneity will inform our efforts to personalize therapy in this disease.",
author = "Sinicato, {Nail{\'u} Ang{\'e}lica} and Mariana Postal and Simone Appenzeller and Niewold, {Timothy B.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s40290-017-0178-6",
language = "English (US)",
volume = "31",
pages = "81--88",
journal = "Pharmaceutical Medicine",
issn = "1178-2595",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Defining Biological Subsets in Systemic Lupus Erythematosus

T2 - Progress Toward Personalized Therapy

AU - Sinicato, Nailú Angélica

AU - Postal, Mariana

AU - Appenzeller, Simone

AU - Niewold, Timothy B.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Systemic lupus erythematosus (SLE) is a heterogeneous disease with respect to disease severity, response to treatment, and organ damage, the pathogenesis of which includes immunological mechanisms that are driven by both genetic and environmental factors. There are clear differences in the pathogenesis of SLE between patients of different ancestral backgrounds, including differences in genetic risk factors, immunological parameters, and clinical manifestations. Patients with high and low levels of type I interferon (IFN) in circulation represent one major biological subset within SLE, and these two groups of patients are present in all ancestral backgrounds. Genetic factors, autoantibodies, and levels of other cytokines all differ between high and low IFN patients. This distinction has also been important in predicting response to treatment with anti-type I IFN therapies, providing a precedent in SLE for biological subsets predicting treatment response. This review highlights some recent developments in defining biological subsets of SLE based on disease pathophysiology, and we speculate how this improved knowledge of disease heterogeneity will inform our efforts to personalize therapy in this disease.

AB - Systemic lupus erythematosus (SLE) is a heterogeneous disease with respect to disease severity, response to treatment, and organ damage, the pathogenesis of which includes immunological mechanisms that are driven by both genetic and environmental factors. There are clear differences in the pathogenesis of SLE between patients of different ancestral backgrounds, including differences in genetic risk factors, immunological parameters, and clinical manifestations. Patients with high and low levels of type I interferon (IFN) in circulation represent one major biological subset within SLE, and these two groups of patients are present in all ancestral backgrounds. Genetic factors, autoantibodies, and levels of other cytokines all differ between high and low IFN patients. This distinction has also been important in predicting response to treatment with anti-type I IFN therapies, providing a precedent in SLE for biological subsets predicting treatment response. This review highlights some recent developments in defining biological subsets of SLE based on disease pathophysiology, and we speculate how this improved knowledge of disease heterogeneity will inform our efforts to personalize therapy in this disease.

UR - http://www.scopus.com/inward/record.url?scp=85016576249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016576249&partnerID=8YFLogxK

U2 - 10.1007/s40290-017-0178-6

DO - 10.1007/s40290-017-0178-6

M3 - Article

AN - SCOPUS:85016576249

VL - 31

SP - 81

EP - 88

JO - Pharmaceutical Medicine

JF - Pharmaceutical Medicine

SN - 1178-2595

IS - 2

ER -